REGN stock verdict - Growth
REGN
REGENERON PHARMACEUTICALS, INC.
GROWTHHealthcare
$788.04
Buy
$788.04
Heavy$743.06Buy$990.74Fair$1,238.43Exit$1,486.12
VALUE70
GROWTH37
QUALITY84
TECHNICAL—
TRUST SCORE
96High
confidence in this read — data completeness, earnings quality & coverage
Technicals: insufficient price history
PROS
- Trades 36% below the model's fair value ($1,238.43)
- Reasonable forward P/E of 12.9× on analyst estimates
- Conservative balance sheet — debt-to-equity of 0.11
- Converts 24% of revenue into free cash flow
CONS
No red flags detected.
✳ Pros and cons are machine-generated from the latest fundamentals and technicals.
EARNINGS QUALITY · we check the accounting so you don't have to
✓Operating cash flow is 108% of net income — profit is backed by real cash
Analysis as of 2026-09-25 · price live, fundamentals from latest filings
Congress Trading — last 90 days
See what senators are buying and selling on REGN. Sign in to unlock.
📊 Options Flow — Put/Call Ratio
FAQ
Why is REGN rated Growth?
REGN (REGENERON PHARMACEUTICALS, INC.) is rated Growth because the model combines fundamentals, price action, and earnings-quality checks. The current signal is Buy. Trades 36% below the model's fair value ($1,238.43) and Reasonable forward P/E of 12.9× on analyst estimates
Is REGN overvalued right now?
REGN is trading at $788.04 versus an estimated fair value of $1,238.43. That puts the stock in growth territory on this framework. The page shows the specific downside checks behind that call.
What should I watch before acting on REGN?
Watch the trust score of 96, the earnings-quality checks, and any red flags. The page includes the key cautions and a plain-English summary.